All you need to know about VIPoma: Review on the latest studies.

Emija Nikola Karele

Journal: Presse medicale (Paris, France : 1983) 2024;53(2):104222

PMID: 38109967

Full Text on Elsevier Science View on PubMed

Abstract

Vasoactive intestinal peptide secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor that is characterized by watery diarrhea, hypokalemia and achlorhydria due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, electrolyte balance correction, pharmacological treatment with somatostatin analogs, surgical resection and chemotherapy. This review aims to provide an insight into the latest research on VIPoma epidemiology, pathophysiology, diagnostics and treatment.

Address: Faculty of Medicine, Riga Stradins University, 16 Dzirciema Street, Riga LV-1007, Latvia. Electronic address: [email protected].

DOI: 10.1016/j.lpm.2023.104222

Link outs

Free resources

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-AKR1B1-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Vipoma, Vasoactive Intestinal Peptide